Medical Device companies planning to enter Europe and the United States must understand the regulatory requirements in both markets. Although both systems aim to protect patient safety and ensure device performance, they use different classification systems, conformity assessment procedures, and approval pathways.
Understanding EU MDR vs FDA requirements helps manufacturers determine the evidence, documentation, and regulatory support needed before launching a Medical Device internationally.
The right approach depends on the device’s intended purpose, risk level, technology, and applicable regulatory requirements. This guide explains the main differences and how to choose the appropriate pathway.
1. Understanding the Medical Device Regulatory Pathway
A Medical Device regulatory pathway defines the steps a manufacturer must complete before placing a device on a particular market.
In the European Union, Medical Devices are primarily regulated under the Medical Device Regulation (EU) 2017/745, commonly known as the EU MDR. Manufacturers must meet applicable safety and performance requirements and complete the relevant conformity assessment process.
In the United States, the Food and Drug Administration (FDA) regulates Medical Devices under the Federal Food, Drug, and Cosmetic Act and related regulations. The required pathway depends on the device classification and whether an appropriate regulatory route is available.
Neither market uses a single approval process for every device. Manufacturers must assess their specific product before selecting a pathway.
2. CE Marking Under EU MDR
CE marking under EU MDR demonstrates that a Medical Device meets the applicable European Union requirements and has completed the required conformity assessment.
Manufacturers must establish compliance with the relevant General Safety and Performance Requirements. Depending on the device, this may involve clinical evaluation, risk management, technical documentation, quality management systems, and post-market surveillance.
Devices are classified into Classes I, IIa, IIb, and III. Active implantable devices are regulated under MDR 2017/745 and are generally classified as Class III
.
For many Class I devices, manufacturers may self-declare conformity. However, notified body involvement is required for Class Is (sterile), Im (measuring), Ir (reusable surgical instruments), and certain Class I devices covered by specific MDR provisions.
.
After satisfying the applicable requirements, the manufacturer prepares the required documentation and issues the EU Declaration of Conformity before affixing the CE mark.
CE marking is not simply a certificate issued by the European Commission. The route depends on the device classification and applicable conformity assessment requirements.
3. FDA 510(k) vs PMA vs De Novo
The FDA 510(k) vs PMA vs De Novo comparison is central to planning entry into the U.S. market.
The FDA uses different pathways based on device classification, risk, and regulatory history.
FDA 510(k)
A 510(k) submission generally demonstrates that a device is substantially equivalent to a legally marketed predicate device. This pathway is commonly used for many Class II devices and certain Class I devices that require a 510(k).
The submission typically includes device descriptions, intended use, technological characteristics, and performance data needed to support substantial equivalence.
Premarket Approval (PMA)
PMA is generally required for Class III devices unless the device type is subject to an alternative classification or regulatory pathway established by FDA
. It involves a more extensive review of scientific evidence supporting the device’s safety and effectiveness.
Clinical data are often important, although the evidence required depends on the device and the available supporting information.
De Novo classification
The De Novo pathway provides a route for certain novel, low-to-moderate-risk devices for which general controls, or general and special controls, can provide reasonable assurance of safety and effectiveness and for which there is no legally marketed predicate suitable for a 510(k).
A successful De Novo request establishes a new device type and classification.
Manufacturers should not select a pathway based on risk alone. They must also consider existing classifications, predicate availability, and applicable FDA requirements.
4. Medical Device Classification EU vs US
The Medical Device classification EU vs US comparison shows why manufacturers should not assume that the same product will receive the same classification in both markets.
The EU MDR uses Classes I, IIa, IIb, and III, applying classification rules based on factors such as intended purpose, duration of use, invasiveness, and potential risk.
The FDA generally classifies devices into Class I, Class II, and Class III. The classification depends on the device type, intended use, and regulatory controls needed to provide reasonable assurance of safety and effectiveness.
| Factor | European Union | United States |
| Classification system | Classes I, IIa, IIb, III | Classes I, II, III |
| Main regulatory framework | EU MDR 2017/745 | Federal Food, Drug, and Cosmetic Act and related regulations |
| Conformity or submission route | Depends on class and conformity assessment rules | Depends on classification and applicable pathway |
| External assessment | Notified body required for many, but not all, devices | FDA review is required for applicable submissions such as 510(k), De Novo, and PMA. Some Class I and Class II devices may be exempt from premarket submission requirements. |
| Market authorization evidence | Conformity assessment and required documentation | Applicable FDA clearance, approval, or authorization |
Classification differences can affect evidence requirements, review planning, costs, and launch timelines. A manufacturer should evaluate the device separately under each jurisdiction’s rules.
5. Medical Device Market Access EU and USA
Planning Medical Device market access EU and USA requires more than preparing one technical file and submitting it to two authorities.
In the EU, manufacturers must meet applicable MDR requirements, complete the relevant conformity assessment, establish post-market surveillance processes, and address registration and economic-operator obligations where applicable. Manufacturers established outside the EU generally need an authorized representative in the EU.
Manufacturers located outside the United States must also designate a U.S. Agent and comply with applicable establishment registration and device listing requirements
. Depending on the product, this may include establishment registration, device listing, a 510(k) clearance, PMA approval, De Novo authorization, or another applicable regulatory route.
A registration or listing alone does not replace a required device clearance or approval.
Companies should plan for labeling, quality systems, clinical evidence, complaint handling, vigilance, and post-market obligations in both markets.
6. Notified Body vs FDA Review
The notified body vs FDA review distinction is important because these organizations have different regulatory roles.
A notified body is an organization designated by an EU Member State to conduct specific conformity assessments under applicable EU legislation. Where required, it assesses whether the manufacturer has demonstrated compliance with relevant requirements. The manufacturer remains responsible for overall compliance and the Declaration of Conformity.
The FDA is a U.S. federal regulatory agency. It reviews applicable submissions, including 510(k) notifications, PMA applications, and De Novo requests. The FDA may also inspect establishments and take regulatory action where appropriate.
A notified body does not replace the FDA, and an FDA clearance or approval does not automatically establish EU MDR compliance.
7. How to Choose the Right Regulatory Strategy
Before selecting a pathway, manufacturers should:
- Define the device’s intended purpose and intended users.
- Determine the classification separately for the EU and U.S. markets.
- Identify applicable conformity assessment or FDA submission requirements.
- Assess existing clinical and performance evidence.
- Evaluate quality management and technical documentation gaps.
- Plan for labeling, registration, and post-market obligations.
- Establish realistic timelines, responsibilities, and budgets.
Early regulatory planning can help identify evidence gaps before they delay a market launch.
Conclusion
EU MDR and FDA pathways differ in classification, conformity assessment, and regulatory review. The EU generally relies on manufacturer conformity assessment, with notified-body involvement where required, while the FDA uses pathways such as 510(k), PMA, and De Novo depending on the device.
Manufacturers should assess each market independently and build a regulatory strategy around the device’s intended use, risk classification, and evidence requirements.
For support with international Medical Device regulatory planning, visit Cliniexperts International.
